

Adherence to malaria treatment policy and prevalence of Pfk13 and background mutations associated with artemisinin resistance emergence in *Plasmodium falciparum* parasites in Uganda

Submission date 25/03/2022	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 01/04/2022	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 28/03/2022	Condition category Infections and Infestations	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Malaria is a serious and sometimes fatal disease caused by a parasite that commonly infects a certain type of mosquito which feeds on humans.

Malaria remains a serious public health problem in Uganda, accounting for 30-50% of out-patient visits, 15-20% of hospital admissions and up to 20% of in-patient deaths. Malaria treatment is threatened by resistance to artemisinin agents, the cornerstone of current treatment modalities. Artemisinins are derived from extracts of sweet wormwood (*Artemisia annua*) and are well established for the treatment of malaria, including highly drug-resistant strains. Efforts to track and contain artemisinin resistance especially in sub-Saharan Africa are hindered by lack of valid molecular markers coupled with inadequate capacity to perform routine parasite sensitivity analysis. Additionally, lack of information on local drivers of artemisinin resistance development and spread further limit development of containment and eradication strategies. The study is screening for the presence of artemisinin resistance in *Plasmodium falciparum* parasites among symptomatic malaria patients in low and high malaria transmission settings in Uganda

Who can participate?

Adult (18 years and above) malaria patients

What does the study involve?

Participants provide a blood sample at a single time point

What are the possible benefits and risks of participating?

There are no anticipated direct benefits and risks to participating in this study. However, participating in the study will help in advancing scientific knowledge on artemisinin resistance.

Where is the study run from?

Makerere University, College of Health Sciences, Department of Pharmacology & Therapeutics (Uganda)

When is the study starting and how long is it expected to run for?

August 2019 to December 2023

Who is funding the study?

European & Developing Countries Clinical Trials Partnership (the Netherlands)

Who is the main contact?

Dr Moses Ocan, ocanmoses@gmail.com

Contact information

Type(s)

Principal investigator

Contact name

Dr Moses Ocan

ORCID ID

<https://orcid.org/0000-0002-8852-820X>

Contact details

Upper Mulago Hill Road

Kampala

Uganda

-

+256 782355302

moses.ocan@mak.ac.ug

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Protocol serial number

SBS 803

Study information

Scientific Title

Predictors of local emergence and spread of artemisinin resistance among Ugandan plasmodium falciparum parasites

Acronym

Pfkelch13 emergence

Study objectives

Research questions

1. What is the extent of adherence to national malaria treatment guidelines/policy in malaria treatment in private hospitals, private pharmacies and public hospitals in low and high malaria transmission settings in Uganda
2. What is the prevalence of Pfk13 single nucleotide polymorphisms and background mutations fd (ferredoxin), arps10 (apicomplast ribosomal protein S10), mdr-2 (multi-drug resistance protein-2) and crt (chloroquine resistance protein) in Plasmodium falciparum parasites in low and high malaria transmission settings in Uganda

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 07/10/2020, School of Biomedical Science Research Ethics Committee (P.O. Box 7072, Kampala, Uganda; +256 752575050; biomedicalresearch62@gmail.com), ref: SBS 803

Study design

Single center observational cross-sectional cohort study

Primary study design

Observational

Study type(s)

Screening

Health condition(s) or problem(s) studied

Screening for occurrence of artemisinin resistance among symptomatic malaria patients

Interventions

The study is screening for the presence of artemisinin resistance in Plasmodium falciparum parasites among symptomatic malaria patients in low and high malaria transmission settings in Uganda. Microscopy is being used to screen for the presence of Plasmodium falciparum parasites in blood samples collected from malaria symptomatic patients. For blood samples where malaria parasites are confirmed, the sample is collected in a dried blood spot Whatman filter paper. The DNA of the parasites are then extracted from the filter paper and screened for the presence of K13 mutations (markers for artemisinin resistance) and background mutations (crt, arps10, fd, mdr-2) using Sanger sequencing method

Approach: (i) Treatment of malaria patients in health facilities (public and private) will be assessed using a checklist to establish adherence to national malaria treatment guidelines, (ii) P. falciparum infected blood samples collected in high and low malaria transmission settings in Uganda will be used. P. falciparum infection will be established using PfHRP-2 Rapid Diagnostic Test (HRP-2 RDT) and microscopy. (iii) Parasite DNA will be extracted and purified using Qiagen-Max kit. Next generation sequencing platform will be used to establish Pfk13 Single nucleotide polymorphisms (SNPs) and genetic background mutations (fd, arps10, mdr2 and crt) in P. falciparum parasites.

Intervention Type

Other

Primary outcome(s)

Artemisinin resistance is measured using K13 gene mutations and background mutations (crt, arps10, fd, mdr-2) at baseline. This being a cross-sectional study, the outcome will be measured once at baseline.

Key secondary outcome(s)

1. Level of adherence to malaria treatment policy measured using a questionnaire and interview guide at baseline
2. Pharmacopoeial quality of ACTs measured using LC-MS at baseline

Completion date

31/12/2023

Eligibility

Key inclusion criteria

1. Symptomatic malaria patients
2. Age 18 years and above
3. Patients with malaria treatment given at a hospital

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Severely ill adult malaria patients
2. Anemic patients (males, Hb < 13g/100ml; non-pregnant females, Hb <12g/100ml; pregnant females, Hb <11g/100ml)
3. Patients with low parasite load (<1000 parasites/ μ l of blood)

Date of first enrolment

05/06/2021

Date of final enrolment

05/06/2022

Locations

Countries of recruitment

Uganda

Study participating centre
Makerere University
College of Health Sciences
Department of Pharmacology & Therapeutics
Upper Mulago Hill Road
Kampala
Uganda
-

Sponsor information

Organisation
European & Developing Countries Clinical Trials Partnership

ROR
<https://ror.org/031jv9v19>

Funder(s)

Funder type
Government

Funder Name
European and Developing Countries Clinical Trials Partnership

Alternative Name(s)
Le partenariat Europe-Pays en développement pour les essais cliniques, A Parceria entre a Europa e os Países em Desenvolvimento para a Realização de Ensaios Clínicos, The European & Developing Countries Clinical Trials Partnership (EDCTP), The European & Developing Countries Clinical Trials Partnership, European and Developing Countries Clinical Trials, EDCTP

Funding Body Type
Private sector organisation

Funding Body Subtype
International organizations

Location
Netherlands

Results and Publications

Individual participant data (IPD) sharing plan

Primary data will be shared with open access journals where the study will be published.

IPD sharing plan summary

Published as a supplement to the results publication